Business

Indian Pharma Stocks Rebound up to 10% as Trump Tariff Clarification Calms Markets

The turnaround follows a rocky end to the previous week, when U.S. President Donald Trump announced a potential 100 percent tariff on imported branded and patented drugs, effective October 1, unless production shifts to U.S. soil. That announcement had unsettled markets and triggered a sell-off in Indian pharma stocks.

• By Newsdesk
• New Delhi
• Sep 30, 2025

Business

Pharmaceutical stocks staged a sharp recovery on Monday after fresh clarity emerged on proposed U.S. tariff policy, with several names surging as much as 10 percent.

Shares of Wockhardt led the rally, jumping over 10 percent, while others—such as Sun Pharma, Lupin, Alembic Pharma, Cipla, Zydus Lifesciences, and Biocon—registered gains of 1–3 percent. The sector’s uplift was reflected in the Nifty Pharma index, which advanced over 1 percent, fueled by strong performances from major constituents.

The turnaround follows a rocky end to the previous week, when U.S. President Donald Trump announced a potential 100 percent tariff on imported branded and patented drugs, effective October 1, unless production shifts to U.S. soil. That announcement had unsettled markets and triggered a sell-off in Indian pharma stocks.

Investor sentiment improved materially once it was clarified that the tariff proposal would apply only to branded and patented drugs—not to generic medicines, which comprise the vast bulk of India’s pharmaceutical exports to the U.S. As a result, fears over drastic export disruptions eased.

Analysts point out that India’s strength in generics — the sector’s primary export segment — insulates many pharmaceutical firms from the proposed tariff’s worst impacts. One market analyst noted that while branded drugs could face pressure, generics account for most of India’s shipments to the U.S., limiting disruption to earnings. Some exporters have begun diversifying to newer markets in Latin America and Africa and ramping up efforts in biopharma and innovation to reduce dependency on the U.S.

Still, caution lingers. The uncertainty surrounding possible future changes in trade policies means that even with today’s rebound, investors will closely monitor supply chains, regulatory shifts, and the pace at which Indian firms may need to build domestic manufacturing capabilities in the U.S.